Safety, Tolerability, and Distribution of Topical Laquinimod Eye Drops , an Innovative ImmunomodulatOr Targeting Aryl hydrocarboN Receptor (AhR): The LION Study
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Laquinimod (Primary)
- Indications Uveitis
- Focus Pharmacokinetics
- Acronyms The LION Study
- 21 Nov 2024 Planned End Date changed from 1 Feb 2025 to 1 Apr 2025.
- 21 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jan 2025.
- 10 Sep 2024 Bioanalytical results presented in an Active Biotech media release.